

## Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immunoncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immunoncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

## BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation

Dec 12 2018, 4:00 AM EST

## BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Dec 3 2018, 6:00 AM EST

## BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development

Nov 14 2018, 4:00 AM EST

## Stock Overview

Symbol	BTAI
Exchange	Nasdaq
Market Cap	52.1m
Last Price	\$3.33
52-Week	\$3.5117 - \$14.7899

12/18/2018 04:00 PM EST

## Investor Relations

Lee Roth  
T: 646-536-7012  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

## Management Team

### Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

### Frank D. Yocca, Ph.D.

Chief Scientific Officer

### Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

### Richard I. Steinhart

Vice President & Chief Financial Officer

### Chids Mahadevan

Vice President, Finance & Chief Accounting Officer

### Chetan D. Lathia, Ph.D.

Senior Vice President & Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

### Cedric Burg, Ph.D.

VP, Head of Global Clinical Operations and Project Management

### Vikas Sharma, Ph.D.

Vice President of Business Development

### Michael De Vivo Ph.D.

Vice President, Neuroscience

### David C. Hanley

Vice President and Head of Global Pharmaceutical Development and Operations

---

## BioXcel Therapeutics, Inc.

555 Long Wharf Drive  
5th Floor  
New Haven, CT 06511  
United States

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.